<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="115788">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01595841</url>
  </required_header>
  <id_info>
    <org_study_id>R-11-774</org_study_id>
    <secondary_id>17839</secondary_id>
    <nct_id>NCT01595841</nct_id>
  </id_info>
  <brief_title>Sirolimus Use in Angioplasty for Vascular Access Extension</brief_title>
  <acronym>SAVE</acronym>
  <official_title>A Randomized Open Label Trial of Oral Sirolimus for Decrease of Stenosis in Arteriovenous Fistula in Hemo-dialysis Patients When Compared With Standard Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lawson Health Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Lawson Health Research Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Dialysis patients presenting for angioplasty intervention for graft failure will be
      randomized to receive either Sirolimus or not receive Sirolimus (standard of care) to assess
      the time from primary failure or angioplasty intervention to second or next angioplasty
      intervention or graft failure.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2011</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">July 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Comparison of the sirolimus group to the control group from time of assisted primary and secondary patency rates to access abandonment</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">36</enrollment>
  <condition>End Stage Renal Disease</condition>
  <condition>Venous Stenosis</condition>
  <arm_group>
    <arm_group_label>Sirolimus</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Not taking Sirolimus</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sirolimus</intervention_name>
    <description>3 mg po od loading dose for two days, then 2 mg po od for thirty days</description>
    <arm_group_label>Sirolimus</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion

          1. hemodialysis patients referred for angioplasty for hemodialysis access stenosis
             through either access flow or clinical monitoring in either an AVF or AVG

          2. &gt; 18 years of age.

          3. Total white blood cell count &gt; 3 x 109 /L and platelet count &gt; 100.0 x 103/uL

          4. Fasting triglycerides &lt; 4.0 mmol/L, fasting cholesterol &lt; 7.8 mmol/L while on optimal
             lipid lowering therapy.

        Exclusion Criteria:

          1. A woman who is pregnant or breastfeeding

          2. Active malignancy

          3. Concomitant treatment with immunosuppressant medications

          4. Active infection or treated for infection within the last 30 days

          5. Pre-existing interstitial lung disease

          6. Thrombocytopenia with platelets less than 100 109/L

          7. Previous renal or other solid organ transplant

          8. Preexisting liver failure

          9. Life expectancy less than 6 months

         10. Planned major surgery or major surgery within the last 6 months

         11. History of malignancy within the previous 5 years (with the exception of adequately
             treated basal cell or squamous cell carcinoma of the skin).

         12. Known history of any coronary intervention within the 6 months prior to current
             screening

         13. Prior or current use of Sirolimus or any of its derivatives within 3 months prior to
             angioplasty

         14. Active gastrointestinal disorder that may interfere with drug absorption

         15. Known to be HIV positive or known active hepatitis B or C infection

         16. Treatment with voriconazole, terfenadine, cisapride, astemizole, pimozide, or
             ketoconazole (known to interact with Sirolimus) that is not discontinued before
             starting Sirolimus treatment.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anthony Jevnikar, MSc MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Lawson Health Research Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>London Health Sciences Centre</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 5A5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mary Jeanne Edgar</last_name>
      <phone>519-685-8500</phone>
      <phone_ext>34755</phone_ext>
    </contact>
    <investigator>
      <last_name>Anthony Jevnikar, MSc MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Regina Qu'Appelle Health Region</name>
      <address>
        <city>Regina</city>
        <state>Saskatchewan</state>
        <zip>S4P 0W5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bonnie Richardson, MD</last_name>
      <phone>306-525-2404</phone>
    </contact>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>September 2016</verification_date>
  <lastchanged_date>September 8, 2016</lastchanged_date>
  <firstreceived_date>May 2, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Lawson Health Research Institute</investigator_affiliation>
    <investigator_full_name>Anthony Jevnikar</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>hemodialysis</keyword>
  <keyword>stenosis</keyword>
  <keyword>angioplasty</keyword>
  <keyword>sirolimus</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Constriction, Pathologic</mesh_term>
    <mesh_term>Kidney Failure, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Sirolimus</mesh_term>
    <mesh_term>Everolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
